Arrowhead Pharmaceuticals Newsroom

Insider Sale: Chief Executive Officer of $ARWR (ARWR) Sells 12,563 Shares

Quiver QuantitativeDec 23 16:46 ET

2024's 'Biggest Loses' That Could See Reversal in 2025

Seeking AlphaDec 23 10:00 ET

Arrowhead Pharmaceuticals Doses First Patients in Trial of Potential Obesity Drug

MT NewswiresDec 23 08:36 ET

Express News | Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of Aro-Inhbe for the Treatment of Obesity

ReutersDec 23 07:30 ET

Arrowhead Pharmaceuticals Insider Sold Shares Worth $567,486, According to a Recent SEC Filing

MT NewswiresDec 23 04:03 ET

H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $80

Moomoo NewsDec 20 14:31 ET · Ratings

Arrowhead Pharmaceuticals Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow JonesDec 20 11:12 ET · Ratings

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BusinesswireDec 19 16:59 ET

Express News | Arrowhead Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersDec 19 16:59 ET

Leadership Transition at Arrowhead Pharmaceuticals' Board

TipRanksDec 18 06:34 ET

In the Wake of Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Latest US$112m Market Cap Drop, Institutional Owners May Be Forced to Take Severe Actions

Simply Wall StDec 17 12:16 ET

B.Riley Financial Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Announces Target Price $51

Moomoo NewsDec 12 08:31 ET · Ratings

B. Riley Lowers Price Target on Arrowhead Pharmaceuticals to $51 From $55, Keeps Buy Rating

MT NewswiresDec 12 07:54 ET · Ratings

Arrowhead Pharmaceuticals: Positioned for Growth With Strategic Partnerships and SiRNA Advancements

TipRanksDec 12 07:35 ET

Chardan Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $60

Moomoo NewsDec 11 21:31 ET · Ratings

Promising Clinical Trial Results Boost Confidence in Arrowhead Pharmaceuticals, Justifying Buy Rating

TipRanksDec 11 21:15 ET · Ratings

Arrowhead Pharmaceuticals Announced Interim Results From A Phase 1/2A Clinical Study Of ARO-CFB, The Company's Investigational RNA Interference (RNAi) Therapeutic Targeting Complement Factor B Being Developed As A Potential Treatment For Complement...

BenzingaDec 11 07:40 ET

Shareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) Have Lost 66%, as Stock Drops 9.3% This Past Week

Yahoo FinanceDec 7 09:31 ET

Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $45

Moomoo NewsDec 5 11:35 ET · Ratings

Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Arrowhead Pharmaceuticals (ARWR) and Heron Therapeutics (HRTX)

TipRanksDec 5 11:10 ET · Ratings